MetaCap

Cencora (COR) vs Nu Skin Enterprises (NUS)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Cencora (COR) has outperformed Nu Skin Enterprises (NUS) over the past year, losing 7.3% versus a loss of 62.1%. Over five years, COR leads with a +182.0% price change compared with -91.4% for NUS. Cencora is the larger company by market cap ($64.71 billion vs $185.0 million), about 349.8 times the size.

On valuation, Nu Skin Enterprises trades at a lower forward P/E (3.4x vs 15.6x for Cencora). Nu Skin Enterprises offers the higher dividend yield (6.32% vs 0.71%). Nu Skin Enterprises converts more of its revenue into profit, with a net margin of 10.8% versus 0.5%.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

COR-7.27%NUS-62.08%
+19%-24%-66%
Nov 21, 20251 yearNov 20, 2026
COR+181.36%NUS-91.88%
+224%+58%-107%
Nov 15, 20215 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

COR versus NUS key metrics
MetricCORNUS
Share price$339.09$3.80
Market cap$64.71B$184.98M
1-day change-0.63%+0.80%
YTD return+0.40%-60.50%
1-year return-7.27%-62.08%
5-year return+182.03%-91.45%
P/E ratio (TTM)18.89—
Forward P/E15.603.36
EPS (TTM)$17.95$-4.86
Dividend yield0.71%6.32%
Annual dividend$2.40$0.24
Revenue (latest FY)$321.33B$1.49B
Revenue growth (YoY)+9.31%-14.26%
Net income (latest FY)$1.55B$160.20M
Gross margin3.57%69.45%
Operating margin0.82%4.43%
Net margin0.48%10.79%
52-week high$377.54$11.67
52-week low$244.82$3.75
Distance from 52-week high-10.18%-67.44%
Analyst consensusbuystrong_buy
Avg. price target upside+12.78%+228.42%
Average volume1.29M533.16K
Shares outstanding190.83M48.68M
Employees47,0002,800
SectorHealth CareHealth Care
IndustryOther PharmaceuticalsOther Pharmaceuticals

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • Cencora is about 349.8 times larger than Nu Skin Enterprises by market value ($64.71B vs $184.98M).
  • COR has outperformed NUS by 54.8 percentage points over the past year.
  • Nu Skin Enterprises offers a meaningfully higher dividend yield (6.32% vs 0.71%).
  • Nu Skin Enterprises is more profitable, keeping 10.8 cents of every revenue dollar as net income versus 0.5 cents for Cencora.
  • Cencora grew revenue faster in its latest fiscal year (+9.31% vs -14.26%).

About Cencora

COR stock →

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally.

Health Care · Other Pharmaceuticals · 47,000 employees

About Nu Skin Enterprises

NUS stock →

Nu Skin Enterprises, Inc., together with its subsidiaries, engages in the development and distribution of various beauty and wellness products worldwide. It offers skin care devices, cosmetics, and other personal care products, including ageLOC LumiSpa, ageLOC LumiSpa iO, and Nu Skin RenuSpa iO; ageLOC TruFace and ageLOC LumiSpa cleansers and devices; Prysm iO, a data-enabled wellness device; and Nutricentials beauty and Beauty Focus wellness brands.

Health Care · Other Pharmaceuticals · 2,800 employees

COR vs NUS FAQ

Which is bigger, Cencora or Nu Skin Enterprises?

Cencora (COR) is larger, with a market capitalization of $64.71B compared with $184.98M for Nu Skin Enterprises (NUS).

Which stock has performed better over the past year, COR or NUS?

COR returned -7.27% over the past 12 months, compared with -62.08% for NUS (price return, excluding dividends). Past performance does not predict future results.

Which pays a higher dividend, Cencora or Nu Skin Enterprises?

Nu Skin Enterprises has the higher yield at 6.32%, compared with 0.71% for Cencora.

Are Cencora and Nu Skin Enterprises in the same industry?

Yes. Both are classified in the Other Pharmaceuticals industry within the Health Care sector.

More comparisons